Longitudinal analysis of serum neurofilament light chain: A potential therapeutic monitoring biomarker for multiple sclerosis

Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis

(2018) Christian Barro et al.   BRAIN

Neurofilament levels, disease activity and brain volume during follow-up in multiple sclerosis

(2018) Irene Håkansson et al.   Journal of Neuroinflammation

Serum neurofilament light chain is a biomarker of acute and chronic neuronal damage in early multiple sclerosis

(2018) Nelly Siller et al.   Multiple Sclerosis Journal

ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis

(2018) Xavier Montalban et al.   Multiple Sclerosis Journal

Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis

(2018) Alexander Rae-Grant et al.   NEUROLOGY

Serum neurofilament light chain is a biomarker of acute and chronic neuronal damage in early multiple sclerosis

(2018) Nelly Siller et al.   Multiple Sclerosis Journal

ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis

(2018) Xavier Montalban et al.   Multiple Sclerosis Journal

Neurofilaments and 10-year follow-up in multiple sclerosis

(2018) Alok Bhan et al.   Multiple Sclerosis Journal

Neurofilaments as biomarkers in neurological disorders

(2018) Michael Khalil et al.   Nature Reviews Neurology

Plasma neurofilament light chain levels in patients with MS switching from injectable therapies to fingolimod

(2017) Fredrik Piehl et al.   Multiple Sclerosis Journal

Monitoring disease activity in multiple sclerosis using serum neurofilament light protein

(2017) Lenka Novakova et al.   NEUROLOGY

Plasma neurofilament light chain levels in patients with MS switching from injectable therapies to fingolimod

(2017) Fredrik Piehl et al.   Multiple Sclerosis Journal

Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa

(2016) Jens Kuhle et al.   CLINICAL CHEMISTRY AND LABORATORY MEDICINE

Cerebrospinal fluid biomarkers of inflammation and degeneration as measures of fingolimod efficacy in multiple sclerosis

(2016) Lenka Novakova et al.   Multiple Sclerosis Journal

Reduced inflammation in relapsing-remitting multiple sclerosis after therapy switch to rituximab

(2016) Pierre de Flon et al.   NEUROLOGY

Cerebrospinal fluid biomarkers of inflammation and degeneration as measures of fingolimod efficacy in multiple sclerosis

(2016) Lenka Novakova et al.   Multiple Sclerosis Journal

Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis

(2015) J. Kuhle et al.   NEUROLOGY

Evaluation of No Evidence of Disease Activity in a 7-Year Longitudinal Multiple Sclerosis Cohort

(2015) Dalia L. Rotstein et al.   JAMA Neurology

Alemtuzumab: A new therapy for active relapsing–remitting multiple sclerosis

(2014) Hans-Peter Hartung et al.   Multiple Sclerosis Journal

MRI lesions as a surrogate for relapses in multiple sclerosis: a meta-analysis of randomised trials

(2013) Maria Pia Sormani et al.   LANCET NEUROLOGY

A comparative study of CSF neurofilament light and heavy chain protein in MS

(2013) Jens Kuhle et al.   Multiple Sclerosis Journal

Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria

(2011) Chris H. Polman et al.   ANNALS OF NEUROLOGY

Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab

(2010) Martin Gunnarsson et al.   ANNALS OF NEUROLOGY

Prevalence of multiple sclerosis in Korea

(2010) N.- H. Kim et al.   NEUROLOGY